Why now

The original draft undersold this. The June cycle is not just a trade pickup. Heartseed announced first-patient dosing in a Phase I/II EMERALD study using catheter delivery of allogeneic iPSC-derived cardiomyocyte spheroids, with the first patient reportedly treated in late March and discharged after an uneventful early course. That makes the timing stronger: a first-in-human or first-in-world delivery-method milestone has moved from lab platform to patient dosing, while still having zero efficacy proof.

Why now

This is much stronger than a generic DMD update because two clocks are now running: Capricor announced five-year HOPE-2 open-label extension data for deramiocel and, separately, an FDA advisory committee meeting was scheduled for July 29 with an August 22 PDUFA target date. That gives VV a clear 'watch before the regulator decides' moment. The human frame is preservation of time in a progressive disease, but the source is company-reported and must be caveated.

Why now

The June 16 UW Medicine profile gives the stroke-recovery trial a named human center, and local coverage adds a shareable musician angle. The now is not device proof; it is that the study moved beyond an abstract implant story to a second enrolled participant with a concrete goal, regaining enough hand function to play music. That makes it a good neuro-recovery watch item with a powerful claim boundary.

Why now

This is publishable because Merck's June 22 topline release says tulisokibart became the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in a Phase 3 ulcerative colitis study. That creates a platform-level story beyond one IBD drug: anti-TL1A has moved from crowded immunology thesis to late-stage proof point. The boundary is that topline remission language is not approval, not full data, and not a safety profile.

Why now

The story reframes a cancer trial as an access problem: a patient could join because the trial reached her community instead of requiring long-distance care.

Why now

This is a rare good-news cancer story where the possible breakthrough is less treatment burden, not more intervention.

Why now

A therapy built for cancer is showing early evidence of resetting immune drivers in severe autoimmune disease.